OptionMetrics and CRSP provide increased integration of U.S. equities and options data for use in academic research ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...

As of 3:05:34 pm GMT-5. Market open. ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

NEW YORK & CHICAGO--(BUSINESS WIRE)--OptionMetrics, an options database and analytics provider for institutional investors and academic researchers worldwide, and CRSP, Center for Research in ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...